← Back to Search

PTSD Therapy for Healthcare Workers' Stress

N/A
Recruiting
Led By Rebecca Sripada, PhD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 6 months
Awards & highlights

Summary

This trial is testing a PTSD therapy to help health system workers cope with stress caused by the pandemic. The therapy will be offered through Employee Assistance Programs to see if it can reduce PTSD symptoms.

Who is the study for?
This trial is for healthcare workers with PTSD symptoms post-COVID-19, who have a PCL-5 score ≥33 and stable psychotropic medication use. Participants must work in a healthcare system with an EAP. Those with active psychosis, high suicide risk, current trauma-focused treatment, non-English speakers, severe cognitive impairment or needing detoxification cannot join.Check my eligibility
What is being tested?
The study compares two treatments for PTSD: standard support from Employee Assistance Programs (EAP Treatment as Usual) versus specialized talk therapy called Prolonged Exposure for Primary Care (PE-PC). The goal is to see if PE-PC can better reduce PTSD symptoms and improve overall functioning.See study design
What are the potential side effects?
While the document doesn't list specific side effects of the interventions being studied, talk therapies like PE-PC may sometimes cause temporary increases in distress due to discussing traumatic events.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Post-Traumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (PCL-5) score
Secondary outcome measures
Change in Burnout based on the Oldenburg Burnout Inventory
Change in Depressive Symptoms based on the Patient Health Questionnaire (PHQ-9)
Change in Job Performance based on the Work Productivity and Activity Impairment Questionnaire (WPAI-GH)
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Prolonged Exposure for Primary CareExperimental Treatment1 Intervention
Group II: EAP Treatment as Usual (TAU)Active Control1 Intervention
Employee Assistance Programs standard treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Prolonged Exposure for Primary Care (PE-PC)
2019
N/A
~120

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Exposure therapy, including Prolonged Exposure (PE), works by gradually and systematically exposing patients to trauma-related memories, feelings, and situations in a controlled environment. This process helps patients confront and process their traumatic experiences, reducing the power these memories have over their emotional and physiological responses. Over time, this can lead to a decrease in PTSD symptoms such as flashbacks, avoidance, and hyperarousal. Selective serotonin reuptake inhibitors (SSRIs) are another common treatment, which work by increasing serotonin levels in the brain to help regulate mood and anxiety. These treatments are crucial for PTSD patients as they address both the psychological and biological aspects of the disorder, providing a comprehensive approach to symptom management and improving overall functioning.
Pilot study on prolonged exposure of Japanese patients with posttraumatic stress disorder due to mixed traumatic events.

Find a Location

Who is running the clinical trial?

University of MichiganLead Sponsor
1,817 Previous Clinical Trials
6,386,952 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,820 Previous Clinical Trials
2,692,409 Total Patients Enrolled
Rebecca Sripada, PhDPrincipal InvestigatorUniversity of Michigan
1 Previous Clinical Trials
35 Total Patients Enrolled

Media Library

Prolonged Exposure for Primary Care (PE-PC) Clinical Trial Eligibility Overview. Trial Name: NCT05751473 — N/A
Post-Traumatic Stress Disorder Research Study Groups: Prolonged Exposure for Primary Care, EAP Treatment as Usual (TAU)
Post-Traumatic Stress Disorder Clinical Trial 2023: Prolonged Exposure for Primary Care (PE-PC) Highlights & Side Effects. Trial Name: NCT05751473 — N/A
Prolonged Exposure for Primary Care (PE-PC) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05751473 — N/A
~246 spots leftby Apr 2026